CYTR Short Information, CytRx Corporation

Twenty Trading Day Totals
Total Shorted Volume	985,562
Total Actual Volume	6,415,516

Averages
Average Short Volume	49,278
Average Short Percentage	39.84%

Is there a CYTR Short Squeeze or Breakout about to happen?

See the CYTR Short Analysis for free Sign up or Login

Stock Date	Open Price	Close Price	High	Low	Total Volume	Short Volume	Short Percentage
2019-06-03	0.38	0.31	0.39	0.30	1,269,537	312,269	80.3260
2019-05-31	0.43	0.3798	0.45	0.37	1,598,758	119,858	34.2114
2019-05-30	0.5199	0.5136	0.5395	0.50	134,006	667	0.7621
2019-05-29	0.56	0.5299	0.56	0.50	283,893	25,836	11.5798
2019-05-28	0.56	0.56	0.5698	0.55	54,609	13,020	55.8750
2019-05-24	0.5403	0.5599	0.56	0.5402	43,807	3,584	39.6197
2019-05-23	0.55	0.5579	0.58	0.5402	90,886	28,344	79.6023
2019-05-22	0.566	0.565	0.5811	0.5401	93,681	16,536	41.7903
2019-05-21	0.58	0.5739	0.59	0.5585	88,606	14,121	31.8564
2019-05-20	0.589	0.5799	0.59	0.57	63,618	14,410	54.4946
2019-05-17	0.58	0.56	0.61	0.5528	261,576	90,295	79.1631
2019-05-16	0.5245	0.57	0.62	0.52	663,835	195,191	67.6005
2019-05-15	0.524	0.525	0.5439	0.50	211,206	8,965	31.7773
2019-05-14	0.5253	0.5178	0.5299	0.4905	62,907	1,176	21.8709
2019-05-13	0.53	0.5185	0.535	0.50	70,707	5,605	42.5298
2019-05-10	0.53	0.53	0.535	0.5042	154,375	1,801	1.7607
2019-05-09	0.5106	0.5245	0.535	0.5042	87,059	13,186	42.0633
2019-05-08	0.548	0.510694	0.56	0.5106	136,877	9,115	24.0997
2019-05-07	0.529	0.53	0.62	0.5042	921,770	104,887	38.7419
2019-05-06	0.52	0.5106	0.53	0.51	123,803	6,696	17.1209

Stock Information

CytRx Corporation Company Name:

CYTR Stock Symbol:

NASDAQ Market:

CytRx Corporation Website:

Get CYTR Alerts

News, Short Squeeze, Breakout and More Instantly...

CYTR - CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

KemPharm Sees Promise in Arimoclomol for Niemann-Pick Disease Type C, and Plans to Resubmit to FDA as Early as Q1 2023 CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and developmen...
CYTR - CytRx Partners with Oncology Development Expert to Advance LADR Platform

Company Begins Planning First-in-Human Studies of Next-Generation LADR Drugs CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, toda...
CYTR - CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress

Thanks Stockholders for Supporting Important Proposal at Recent Special Meeting CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, t...